Literature DB >> 12746213

Alterations in lipid kinetics in men with HIV-dyslipidemia.

D N Reeds1, B Mittendorfer, B W Patterson, W G Powderly, K E Yarasheski, S Klein.   

Abstract

Hypertriglyceridemia is common in individuals with human immunodeficiency (HIV) infection, but the mechanisms responsible for increased plasma triglyceride (TG) concentrations are not clear. We evaluated fatty acid and VLDL-TG kinetics during basal conditions and during a glucose infusion that resulted in typical postprandial plasma glucose and insulin concentrations in six men with HIV-dyslipidemia [body mass index (BMI): 28 +/- 2 kg/m2] and six healthy men (BMI: 26 +/- 2 kg/m2). VLDL-TG secretion and palmitate rate of appearance (Ra) in plasma were measured by using stable-isotope-labeled tracer techniques. Basal palmitate Ra and VLDL-TG secretion rates were greater (P < 0.01 for both) in men with HIV-dyslipidemia (1.04 +/- 0.07 micromol palmitate x kg-1 x min-1 and 5.7 +/- 0.6 micromol VLDL-TG x l plasma-1 x min-1) than in healthy men (0.67 +/- 0.08 micromol palmitate. kg-1 x min-1 and 3.0 +/- 0.5 micromol VLDL-TG x l plasma-1 x min-1). Basal VLDL-TG plasma clearance was lower in men with HIV-dyslipidemia (13 +/- 1 ml/min) than in healthy men (19 +/- 2 ml/min; P < 0.05). Glucose infusion decreased palmitate Ra (by approximately 50%) and the VLDL-TG secretion rate (by approximately 30%) in both groups, but the VLDL-TG secretion rate remained higher (P < 0.05) in subjects with HIV-dyslipidemia. These findings demonstrate that increased secretion of VLDL-TG and decreased plasma VLDL-TG clearance, during both fasting and fed conditions, contribute to hypertriglyceridemia in men with HIV-dyslipidemia. Although it is likely that increased free fatty acid release from adipose tissue contributes to the increase in basal VLDL-TG concentration, other factors must be involved, because insulin-induced suppression of lipolysis and systemic fatty acid availability did not normalize the VLDL-TG secretion rate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746213     DOI: 10.1152/ajpendo.00118.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  31 in total

Review 1.  Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy.

Authors:  Rajagopal V Sekhar; Farook Jahoor; Henry J Pownall; Christie M Ballantyne; Ashok Balasubramanyam
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

2.  Maternal post-absorptive leucine kinetics during late pregnancy in US women with HIV taking antiretroviral therapy: a cross-sectional pilot study.

Authors:  W Todd Cade; Gautam K Singh; Mark R Holland; Dominic N Reeds; E Turner Overton; Nancy Cibulka; Karen Bahow; Rachel Presti; Andrea Stephens; Alison G Cahill
Journal:  Clin Nutr ESPEN       Date:  2015-08-01

3.  Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.

Authors:  Colleen Hadigan; James Liebau; Martin Torriani; Rebecca Andersen; Steven Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

Review 4.  The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.

Authors:  Grace A Lee; Madhu N Rao; Carl Grunfeld
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

Review 5.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

Review 6.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

7.  Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr.

Authors:  N Agarwal; A Balasubramanyam
Journal:  Adipocyte       Date:  2014-10-30       Impact factor: 4.534

8.  HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation.

Authors:  Neeti Agarwal; Dinakar Iyer; Sanjeet G Patel; Rajagopal V Sekhar; Terry M Phillips; Ulrich Schubert; Toni Oplt; Eric D Buras; Susan L Samson; Jacob Couturier; Dorothy E Lewis; Maria C Rodriguez-Barradas; Farook Jahoor; Tomoshige Kino; Jeffrey B Kopp; Ashok Balasubramanyam
Journal:  Sci Transl Med       Date:  2013-11-27       Impact factor: 17.956

9.  Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

Authors:  Diane C Adler-Wailes; Hanguan Liu; Faiyaz Ahmad; Ningping Feng; Constantine Londos; Vincent Manganiello; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

10.  Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.

Authors:  Catherine N Vu; Raul Ruiz-Esponda; Eric Yang; Evelyn Chang; Baiba Gillard; Henry J Pownall; Ron C Hoogeveen; Ivonne Coraza; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2013-03-19       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.